Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug

(Reuters) - Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company's breast cancer drug, sending its shares down 30 percent.